Neuroglee Therapeutics

Executive Summary

Neuroglee Therapeutics is a Singapore-based digital health company founded in 2020, specializing in value-based, physician-led dementia and memory-care services delivered via a telehealth platform and advanced analytics. The company has partnered with the Mayo Clinic to enhance its clinical credibility and expand its reach. With a commercial-stage status and a workforce of 50-200 employees, Neuroglee is positioned to address the growing global burden of cognitive impairment, leveraging digital tools to improve patient outcomes and reduce healthcare costs. The platform combines remote monitoring, data analytics, and personalized care plans, making it a scalable solution for aging populations in Asia and beyond. The dementia care market is expanding rapidly due to rising prevalence and a shift toward home-based care models. Neuroglee’s partnership with Mayo Clinic provides a strong competitive edge, enabling access to world-class clinical expertise and validation. However, the company faces challenges including regulatory hurdles, competition from other digital health startups, and the need for reimbursement clarity. Despite these risks, Neuroglee’s focus on integrated, analytics-driven care positions it well for growth. Conviction score: 65, reflecting a solid business model with clear market need but limited public data on financial traction.

Upcoming Catalysts (preview)

• Q2 2025Mayo Clinic partnership expansion into Asian markets70% success
• Q4 2025Launch of AI-powered predictive analytics module for early dementia detection60% success
• Q1 2026First major health system contract in the U.S. or Europe50% success